"Similarly, in metastatic kidney cancer, researchers showed that tracking ctDNA over time can offer important insights for patients receiving standard immunotherapy or targeted drugs. They found that patients whose ctDNA remained undetectable had much longer periods without disease progression, while those with detectable ctDNA were more likely to experience relapse, revealing its potential to monitor remission and relapse in real time (1088)Basu A, et al. (2024) JCO Precis Oncol, 8: e2400667.."